Delphi advisor in connection with rights issue and listing of Fluicell AB (Publ) on Nasdaq First North
April, 2018 - Stockholm, Sweden
Delphi has acted as legal advisor to Fluicell AB (publ) in connection to a rights issue of 32,7 MSEK and listing on Nasdaq First North. The first day of trade is April 18.
Fluicell is based in Gothenburg Sweden and the company has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell's existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled. More information about the company is found on http://fluicell.com.
The Delphi team mainly consisted of Andreas Wirén (Partner), Daniel Jessen Winbo (Senior Associate) and Anders Hulegårdh (Partner).
Contact:
Andreas Wirén
Partner/Advokat
Delphi
Ph. +46 709 25 25 47
email: [email protected]
